J&J shares hit new high on strong drug sales, weaker dollar
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall, dragged by Alphabet and megacap tech; focus on Iran
- Oil falls almost 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Piper Jaffray Raises Price Target on Johnson & Johnson (JNJ) Following 1Q Report
April 20, 2016 7:42 AM EDTPiper Jaffray reiterated a Neutral rating on Johnson & Johnson (NYSE: JNJ), and raised the price target to $106.00 (from $105.00), following the company's 1Q earnings report. In Pharma, total sales of $8.2B and key drug sales were slightly better than estimates. The Medical Device segment generated revenue of $6.11B,... More
